Neuca SA
WSE:NEU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (17.6), the stock would be worth zł1 562.45 (120% upside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 8 | zł710 |
0%
|
| 3-Year Average | 17.6 | zł1 562.45 |
+120%
|
| 5-Year Average | 14.5 | zł1 290.34 |
+82%
|
| Industry Average | 16.9 | zł1 502.36 |
+112%
|
| Country Average | 15.6 | zł1 390.72 |
+96%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| PL |
N
|
Neuca SA
WSE:NEU
|
3.2B PLN | 8 | 20.4 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
100.3B USD | 10.6 | 23.1 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
59.5B USD | 18.1 | 36.6 | |
| US |
|
Cencora Inc
NYSE:COR
|
59.9B USD | 18.2 | 36.9 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
45.5B USD | 9.3 | 27.4 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
32.1B AUD | 62.5 | 35.3 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
63.4B CNY | 19.7 | 11.1 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
58.5B CNY | 158.3 | 20.6 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
8.6B USD | 22.2 | 21.7 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | -285 | 89.6 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
57.6B HKD | 0.5 | 7.2 |
Market Distribution
| Min | 0.3 |
| 30th Percentile | 8.2 |
| Median | 15.6 |
| 70th Percentile | 26.6 |
| Max | 1 085.9 |
Other Multiples
Neuca SA
Glance View
NEUCA SA engages in the wholesale of pharmaceutical products. The company is headquartered in Torun, Woj. Kujawsko - Pomorskie and currently employs 3,852 full-time employees. The company went IPO on 2004-09-30. The firm is mainly involved in the distribution of drugs to pharmacies. The company also operates in other sectors of the health market, such as production of drugs, supplements and cosmetics under its own brand, clinical trials, telemedicine, Information Technology (IT) solutions and e-commerce in the health care industry.
